Derek DiRocco - 13 Jun 2023 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role: Director
Signature: /s/ Adi Osovsky, as Attorney-in-Fact
Issuer symbol: ITOS
Transactions as of: 13 Jun 2023
Net transactions value: $0
Form type: 4
Filing time: 15 Jun 2023, 19:53:23 UTC
Previous filing: 13 Feb 2023
Next filing: 23 Jun 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ITOS	Stock Option (Right to Buy)	Award	$0	+22,383		$0.000000	22,383	13 Jun 2023	Common Stock	22,383	$14.77	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.

Content

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.